Bioequivalence testing of topical dermatological formulations, the gap between science and legislation
Bioavailability concerns for topical dermatological products are complex and it is especially difficult to determine the bioequivalence of similar topical formulations. Since only small amounts of drug dispersed in an appropriate vehicle are applied to the skin, the amount of drug that actually reac...
Main Authors: | Schwarb, F P, Smith, E W, Haigh, J M, Surber, C |
---|---|
Format: | Others |
Language: | English |
Published: |
1998
|
Online Access: | http://hdl.handle.net/10962/d1006608 |
Similar Items
-
Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin
by: Schwarb, F P, et al.
Published: (1999) -
Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing
by: Demana, P H, et al.
Published: (1997) -
Bioequivalence of Topical Clotrimazole Formulations: An Improved Tape Stripping Method
by: Natalie Rae Parfitt, et al.
Published: (2011-09-01) -
A Study of Formulation Robustness of Bioequivalence Tests
by: Shyu, Ji-How, et al.
Published: (1996) -
Revisiting FDA’s 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based Recommendations
by: Deniz Ozdin, et al.
Published: (2018-11-01)